BRCA2 and ovarian serous adenocarcinoma: Interestingly, a very recent whole exome sequencing study of 31 high-grade serous ovarian cancer specimens did not show evidence of reactivating mutations in BRCA1 or BRCA2 in platinum-sensitive, relapsed tumors after a single line of standard-of-care, platinum-based chemotherapy compared with untreated primary tumors [62].